Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)

Kidney International

Volumn 80, Issue 6, 2011, Pages 572-586

  Herzog, Charles A ^a,b   Asinger, Richard W ^a,b   Berger, Alan K ^b   Charytan, David M ^c   Díez, Javier ^d   Hart, Robert G ^e   Eckardt, Kai Uwe ^f   Kasiske, Bertram L ^a,b   McCullough, Peter A ^g   Passman, Rod S ^h   Deloach, Stephanie S ⁱ   Pun, Patrick H ^j   Ritz, Eberhard ^k  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF NAVARRA   (Spain)

^e MCMASTER UNIVERSITY   (Canada)

^f UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^g St John Providence Health System   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ THOMAS JEFFERSON UNIVERSITY   (United States)

^j DUKE UNIVERSITY   (United States)

^k UNIVERSITY OF HEIDELBERG   (Germany)

more..

Author keywords

atrial fibrillation; heart failure; myocardial infarction; peripheral arterial disease; stroke; sudden death

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUFADIENOLIDE DERIVATIVE; CILOSTAZOL; CLOPIDOGREL; DABIGATRAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; EPTIFIBATIDE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LEVOSIMENDAN; MILRINONE; PHOSPHATE; PLACEBO; PREALBUMIN; THIAZIDE DIURETIC AGENT; TISSUE PLASMINOGEN ACTIVATOR; TROPONIN; TROPONIN C; TROPONIN T; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; UREA; WARFARIN;

ANGIOCARDIOGRAPHY; ANKLE BRACHIAL INDEX; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLEEDING; BLOOD CLOT LYSIS; BLOOD PRESSURE REGULATION; BLOOD VESSEL CALCIFICATION; BRAIN ANGIOGRAPHY; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CALCINOSIS; CALCIUM INTAKE; CARDIOVASCULAR DISEASE; CAROTID ENDARTERECTOMY; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEMATOCRIT; HEMODIALYSIS; HUMAN; INCIDENCE; KINESIOTHERAPY; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT COUNSELING; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHARMACODYNAMICS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RISK FACTOR; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; SODIUM RESTRICTION; ST SEGMENT; STRESS ECHOCARDIOGRAPHY; STROKE; SUDDEN DEATH; TREATMENT CONTRAINDICATION;

EID: 80052296951     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.223     Document Type: Conference Paper

References (212)

1. Nakano T, Ninomiya T, Sumiyoshi S et al. Association of kidney function with coronary atherosclerosis and calcification in autopsy samples from Japanese elders: the Hisayama study. Am J Kidney Dis 2010; 55: 21-30.
2. Chonchol M, Whittle J, Desbien A et al. Chronic kidney disease is associated with angiographic coronary artery disease. Am J Nephrol 2008; 28: 354-360.
3. Ix JH, Shlipak MG, Liu HH et al. Association between renal insufficiency and inducible ischemia in patients with coronary artery disease: the heart and soul study. J Am Soc Nephrol 2003; 14: 3233-3238. (Pubitemid 37509298)
4. Marwick TH, Steinmuller DR, Underwood DA et al. Ineffectiveness of dipyridamole SPECT thallium imaging as a screening technique for coronary artery disease in patients with end-stage renal failure. Transplantation 1990; 49: 100-103. (Pubitemid 20051594)
5. Joki N, Hase H, Nakamura R et al. Onset of coronary artery disease prior to initiation of haemodialysis in patients with end-stage renal disease. Nephrol Dial Transplant 1997; 12: 718-723. (Pubitemid 27170426)
6. Ohtake T, Kobayashi S, Moriya H et al. High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination. J Am Soc Nephrol 2005; 16: 1141-1148. (Pubitemid 41710326)
7. deFilippi C, Wasserman S, Rosanio S et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 2003; 290: 353-359. (Pubitemid 37430521)
8. Gibson CM, Pinto DS, Murphy SA et al. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol 2003; 42: 1535-1543. (Pubitemid 37378428)
9. Shlipak MG, Heidenreich PA, Noguchi H et al. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 2002; 137: 555-562.
10. Wright RS, Reeder GS, Herzog CA et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 2002; 137: 563-570.
11. Al SJ, Reddan DN, Williams K et al. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulaton 2002; 106: 974-980. (Pubitemid 34925333)
12. Anavekar NS, McMurray JJ, Velazquez EJ et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285-1295. (Pubitemid 39258422)
13. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
14. Matsushita K, van d V, Astor BC et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073-2081.
15. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998; 339: 799-805. (Pubitemid 28447453)
16. US Renal Data System. USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease & End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2008.
17. Longenecker JC, Coresh J, Powe NR et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol 2002; 13: 1918-1927. (Pubitemid 34700618)
18. Weiner DE, Tighiouart H, Elsayed EF et al. The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol 2007; 50: 217-224. (Pubitemid 47031564)
19. Fleischmann EH, Bower JD, Salahudeen AK. Are conventional cardiovascular risk factors predictive of two-year mortality in hemodialysis patients? Clin Nephrol 2001; 56: 221-230. (Pubitemid 32827558)
20. Kalantar-Zadeh K, Block G, Humphreys MH et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793-808. (Pubitemid 36315558)
21. Bhatt DL. Anti-inflammatory agents and antioxidants as a possible 'third great wave' in cardiovascular secondary prevention. Am J Cardiol 2008; 101: 4D-13D.
22. Weiner DE, Tighiouart H, Elsayed EF et al. Inflammation and cardiovascular events in individuals with and without chronic kidney disease. Kidney Int 2008; 73: 1406-1412. (Pubitemid 351770495)
23. Menon V, Greene T, Wang X et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005; 68: 766-772. (Pubitemid 43323132)
24. Bayes B, Pastor MC, Bonal J et al. Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrol Dial Transplant 2003; 18: 106-112. (Pubitemid 36104485)
25. Briet M, Schiffrin EL. Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol 2010; 6: 261-273.
26. Giovannucci E, Liu Y, Hollis BW et al. 25-Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 2008; 168: 1174-1180. (Pubitemid 351831400)
27. Kovesdy CP, Ahmadzadeh S, Anderson JE et al. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008; 168: 397-403. (Pubitemid 351350586)
28. Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592.
29. Schmidt A, Stefenelli T, Schuster E et al. Informational contribution of noninvasive screening tests for coronary artery disease in patients on chronic renal replacement therapy. Am J Kidney Dis 2001; 37: 56-63. (Pubitemid 32055019)
30. Karthikeyan V, Ananthasubramaniam K. Coronary risk assessment and management options in chronic kidney disease patients prior to kidney transplantation. Curr Cardiol Rev 2009; 5: 177-186.
31. Taylor AJ, Cerqueira M, Hodgson JM et al. ACCF/SCCT/ACR/AHA/ASE/ASNC/ NASCI/SCAI/SCMR 2010 Appropriate use Criteria for Cardiac Computed Tomography: a Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the Society of Cardiovascular Computed Tomography, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology, the North American Society for Cardiovascular Imaging, the Society for Cardiovascular Angiography and Interventions, and the Society for Cardiovascular Magnetic Resonance. Circulation 2010; 122: e525-e555.
32. Hendel RC, Berman DS, Di Carli MF et al. ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/ SNM 2009 Appropriate Use Criteria for Cardiac Radionuclide Imaging: a Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the American Society of Nuclear Cardiology, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society of Nuclear Medicine. Circulation 2009; 119: e561-e587.
33. Vandenberg BF, Rossen JD, Grover-McKay M et al. Evaluation of diabetic patients for renal and pancreas transplantation: noninvasive screening for coronary artery disease using radionuclide methods. Transplantation 1996; 62: 1230-1235. (Pubitemid 27008545)
34. Bangalore S, Yao SS, Chaudhry FA. Usefulness of stress echocardiography for risk stratification and prognosis of patients with left ventricular hypertrophy. Am J Cardiol 2007; 100: 536-543. (Pubitemid 47094703)
35. Yuda S, Khoury V, Marwick TH. Influence of wall stress and left ventricular geometry on the accuracy of dobutamine stress echocardiography. J Am Coll Cardiol 2002; 40: 1311-1319.
36. Herzog CA, Marwick TH, Pheley AM et al. Dobutamine stress echocardiography for the detection of significant coronary artery disease in renal transplant candidates. Am J Kidney Dis 1999; 33: 1080-1090. (Pubitemid 29252678)
37. Sharma R, Mehta RL, Brecker SJ et al. The diagnostic and prognostic value of tissue Doppler imaging during dobutamine stress echocardiography in end-stage renal disease. Coron Artery Dis 2009; 20: 230-237.
38. Herzog CA, Littrell K, Arko C et al. Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: a collaborative project of the United States Renal Data System and the National Registry of Myocardial Infarction. Circulation 2007; 116: 1465-1472. (Pubitemid 47480637)
39. Sosnov J, Lessard D, Goldberg RJ et al. Differential symptoms of acute myocardial infarction in patients with kidney disease: a community-wide perspective. Am J Kidney Dis 2006; 47: 378-384. (Pubitemid 43255170)
40. Freda BJ, Tang WH, Van LF et al. Cardiac troponins in renal insufficiency: review and clinical implications. J Am Coll Cardiol 2002; 40: 2065-2071. (Pubitemid 36005889)
41. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-S119. (Pubitemid 28527268)
42. Kovesdy CP, Anderson JE. Reverse epidemiology in patients with chronic kidney disease who are not yet on dialysis. Semin Dial 2007; 20: 566-569.
43. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ et al. Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: the 58th annual fall conference and scientific sessions. Hypertension 2005; 45: 811-817. (Pubitemid 40418386)
44. Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int 2006; 70: 2021-2030. (Pubitemid 44863392)
45. Coca SG, Krumholz HM, Garg AX et al. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 2006; 296: 1377-1384. (Pubitemid 44427424)
46. Williams ME, Lacson Jr E, Wang W et al. Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent Cox model analyses. Clin J Am Soc Nephrol 2010; 5: 1595-1601.
47. Shurraw S, Majumdar SR, Thadhani R et al. Glycemic control and the risk of death in 1,484 patients receiving maintenance hemodialysis. Am J Kidney Dis 2010; 55: 875-884.
48. Zager PG, Nikolic J, Brown RH et al. 'U' curve association of blood pressure and mortality in hemodialysis patients. Kidney Int 1998; 54: 561-569. (Pubitemid 28357420)
49. Agarwal R. Blood pressure and mortality among hemodialysis patients. Hypertension 2010; 55: 762-768.
50. Isbel NM, Haluska B, Johnson DW et al. Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function. Am Heart J 2006; 151: 745-753. (Pubitemid 43290274)
51. Jardine MJ, Ninomiya T, Perkovic V et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol 2010; 56: 956-965.
52. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
53. Tonelli M, Isles C, Curhan GC et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004; 110: 1557-1563. (Pubitemid 39297976)
54. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248. (Pubitemid 41058323)
55. Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-1407.
56. The SHARP Collaborative Group. Should We Reduce LDL Cholesterol in Patients with Chronic Kidney Disease? The Results of the Study of Heart and Renal Protection (SHARP). American Society of Nephrology Renal Week 2010: Denver CO.
57. Keltai M, Tonelli M, Mann JF et al. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. Eur J Cardiovasc Prev Rehabil 2007; 14: 312-318. (Pubitemid 46650089)
58. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 2003; 42: 201-208. (Pubitemid 36851405)
59. Tsai TT, Maddox TM, Roe MT et al. Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention. JAMA 2009; 302: 2458-2464.
60. Chan MY, Becker RC, Sim LL et al. Reperfusion strategy and mortality in ST-elevation myocardial infarction among patients with and without impaired renal function. Ann Acad Med Singapore 2010; 39: 179-184.
61. Bavry AA, Kumbhani DJ, Rassi AN et al. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol 2006; 48: 1319-1325. (Pubitemid 44436821)
62. Anderson JL, Adams CD, Antman EM et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2007; 116: e148-e304.
63. Charytan DM, Wallentin L, Lagerqvist B et al. Early angiography in patients with chronic kidney disease: a collaborative systematic review. Clin J Am Soc Nephrol 2009; 4: 1032-1043.
64. Szummer K, Lundman P, Jacobson SH et al. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). Circulation 2009; 120: 851-858.
65. Fraker Jr TD, Fihn SD, Gibbons RJ et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. Circulation 2007; 116: 2762-2772. (Pubitemid 350291248)
66. King III SB, Smith Jr SC, Hirshfeld Jr JW et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 2008; 117: 261-295.
67. Sedlis SP, Jurkovitz CT, Hartigan PM et al. Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney disease. Am J Cardiol 2009; 104: 1647-1653.
68. Ix JH, Mercado N, Shlipak MG et al. Association of chronic kidney disease with clinical outcomes after coronary revascularization: the Arterial Revascularization Therapies Study (ARTS). Am Heart J 2005; 149: 512-519. (Pubitemid 40585415)
69. Liu JY, Birkmeyer NJ, Sanders JH et al. Risks of morbidity and mortality in dialysis patients undergoing coronary artery bypass surgery. Circulation 2000; 102: 2973-2977.
70. Charytan DM, Kuntz RE. Risks of coronary artery bypass surgery in dialysis-dependent patients-analysis of the 2001 National Inpatient Sample. Nephrol Dial Transplant 2007; 22: 1665-1671. (Pubitemid 47073766)
71. Cooper WA, O'Brien SM, Thourani VH et al. Impact of renal dysfunction on outcomes of coronary artery bypass surgery: results from the Society of Thoracic Surgeons National Adult Cardiac Database. Circulation 2006; 113: 1063-1070.
72. Herzog CA, Ma JZ, Collins AJ. Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation 2002; 106: 2207-2211. (Pubitemid 35222214)
73. Szczech LA, Reddan DN, Owen WF et al. Differential survival after coronary revascularization procedures among patients with renal insufficiency. Kidney Int 2001; 60: 292-299. (Pubitemid 32587567)
74. Wang ZJ, Zhou YJ, Liu YY et al. Comparison of drug-eluting stents and coronary artery bypass grafting for the treatment of multivessel coronary artery disease in patients with chronic kidney disease. Circ J 2009; 73: 1228-1234.
75. Herzog CA, Solid CA. Long-term survival and repeat revascularization in U.S. dialysis patients after surgical versus percutaneous coronary intervention. [abstract]. J Am Soc Nephrol 2009; 20: 41A.
76. Ronco C, McCullough P, Anker SD et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 2010; 31: 703-711.
77. Schrier RW. Cardiorenal versus renocardiac syndrome: is there a difference? Nat Clin Pract Nephrol 2007; 3: 637. (Pubitemid 350146967)
78. Das M, Aronow WS, McClung JA et al. Increased prevalence of coronary artery disease, silent myocardial ischemia, complex ventricular arrhythmias, atrial fibrillation, left ventricular hypertrophy, mitral annular calcium, and aortic valve calcium in patients with chronic renal insufficiency. Cardiol Rev 2006; 14: 14-17. (Pubitemid 44378519)
79. Bagshaw SM, Cruz DN, Aspromonte N et al. Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrol Dial Transplant 2010; 25: 1406-1416.
80. US Renal Data System. USRDS 2004 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2004.
81. Ahmed A, Rich MW, Sanders PW et al. Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol 2007; 99: 393-398.
82. McCullough PA. Cardiovascular disease in chronic kidney disease from a cardiologist's perspective. Curr Opin Nephrol Hypertens 2004; 13: 591-600. (Pubitemid 39506906)
83. Guerin AP, Pannier B, Marchais SJ et al. Arterial structure and function in end-stage renal disease. Curr Hypertens Rep 2008; 10: 107-111.
84. Redheuil A, Yu WC, Wu CO et al. Reduced ascending aortic strain and distensibility: earliest manifestations of vascular aging in humans. Hypertension 2010; 55: 319-326.
85. Cerasola G, Nardi E, Palermo A et al. Epidemiology and pathophysiology of left ventricular abnormalities in chronic kidney disease: a review. J Nephrol 2011; 24: 1-10.
86. Puschett JB, Agunanne E, Uddin MN. Emerging role of the bufadienolides in cardiovascular and kidney diseases. Am J Kidney Dis 2010; 56: 359-370.
87. Lopez B, Gonzalez A, Hermida N et al. Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide. Kidney Int Suppl 2008; 74: S19-S23.
88. Curtis BM, Parfrey PS. Congestive heart failure in chronic kidney disease: disease-specific mechanisms of systolic and diastolic heart failure and management. Cardiol Clin 2005; 23: 275-284. (Pubitemid 41097351)
89. McIntyre CW. Haemodialysis-induced myocardial stunning in chronic kidney disease-a new aspect of cardiovascular disease. Blood Purif 2010; 29: 105-110.
90. Pecoits-Filho R, Barberato SH. Echocardiography in chronic kidney disease: diagnostic and prognostic implications. Nephron Clin Pract 2010; 114: c242-c247.
91. National Kidney Foundation. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45: S1-S153.
92. Foley RN, Parfrey PS, Kent GM et al. Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 2000; 11: 912-916. (Pubitemid 30241725)
93. Zoccali C, Benedetto FA, Mallamaci F et al. Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int 2004; 65: 1492-1498. (Pubitemid 38406992)
94. Iwanaga Y, Miyazaki S. Heart failure, chronic kidney disease, and biomarkers-an integrated viewpoint. Circ J 2010; 74: 1274-1282.
95. Wu AH, Jaffe AS, Apple FS et al. National academy of clinical biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. Clin Chem 2007; 53: 2086-2096. (Pubitemid 350197291)
96. Roberts MA, Hare DL, Macmillan N et al. Serial increased cardiac troponin T predicts mortality in asymptomatic patients treated with chronic haemodialysis. Ann Clin Biochem 2009; 46: 291-295.
97. Apple FS, Murakami MM, Pearce LA et al. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 2002; 106: 2941-2945. (Pubitemid 35424746)
98. Desai AA, Nissenson A, Chertow GM et al. The relationship between laboratory-based outcome measures and mortality in end-stage renal disease: a systematic review. Hemodial Int 2009; 13: 347-359.
99. Dickstein K, Cohen-Solal A, Filippatos G et al. ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388-2442.
100. Davenport A, Anker SD, Mebazaa A et al. ADQI 7: the clinical management of the Cardio-Renal syndromes: work group statements from the 7th ADQI consensus conference. Nephrol Dial Transplant 2010; 25: 2077-2089.
101. Cice G, Di BA, D'Isa S et al. Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. J Am Coll Cardiol 2010; 56: 1701-1708.
102. Erdmann E, Lechat P, Verkenne P et al. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 2001; 3: 469-479. (Pubitemid 32776874)
103. Cice G, Ferrara L, D'Andrea A et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003; 41: 1438-1444. (Pubitemid 36543357)
104. Sikole A, Polenakovic M, Spirovska V et al. Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients. Artif Organs 1993; 17: 977-984. (Pubitemid 24025978)
105. Parfrey PS, Foley RN, Wittreich BH et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005; 16: 2180-2189. (Pubitemid 41716451)
106. Eckardt KU, Scherhag A, Macdougall IC et al. Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD. J Am Soc Nephrol 2009; 20: 2651-2660.
107. Anker SD, Comin CJ, Filippatos G et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436-2448.
108. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098. (Pubitemid 44749317)
109. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032.
110. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252. (Pubitemid 34754068)
111. Russo D, Miranda I, Ruocco C et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 2007; 72: 1255-1261. (Pubitemid 350059663)
112. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; 76: S1-S130.
113. Navaneethan SD, Palmer SC, Vecchio M et al. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database Systematic Review 2011; 2: CD006023.
114. Davenport A, Cox C, Thuraisingham R. The importance of dialysate sodium concentration in determining interdialytic weight gains in chronic hemodialysis patients: the PanThames Renal Audit. Int J Artif Organs 2008; 31: 411-417. (Pubitemid 351983354)
115. Asci G, Ozkahya M, Duman S et al. Volume control associated with better cardiac function in long-term peritoneal dialysis patients. Perit Dial Int 2006; 26: 85-88. (Pubitemid 44339666)
116. Basile C, Lomonte C, Vernaglione L et al. The relationship between the flow of arteriovenous fistula and cardiac output in haemodialysis patients. Nephrol Dial Transplant 2008; 23: 282-287. (Pubitemid 351767368)
117. Bock JS, Gottlieb SS. Cardiorenal syndrome: new perspectives. Circulation 2010; 121: 2592-2600.
118. Lee M, Saver JL, Chang KH et al. Low glomerular filtration rate and risk of stroke: meta-analysis. BMJ 2010; 341: c4249.
119. Seliger SL, Gillen DL, Longstreth Jr WT et al. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int 2003; 64: 603-609. (Pubitemid 36871932)
120. Sozio SM, Armstrong PA, Coresh J et al. Cerebrovascular disease incidence, characteristics, and outcomes in patients initiating dialysis: the choices for healthy outcomes in caring for ESRD (CHOICE) study. Am J Kidney Dis 2009; 54: 468-477.
121. Toyoda K, Fujii K, Fujimi S et al. Stroke in patients on maintenance hemodialysis: a 22-year single-center study. Am J Kidney Dis 2005; 45: 1058-1066. (Pubitemid 40806519)
122. Boaz M, Smetana S, Weinstein T et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356: 1213-1218.
123. Toyoda K, Fujii K, Ando T et al. Incidence, etiology, and outcome of stroke in patients on continuous ambulatory peritoneal dialysis. Cerebrovasc Dis 2004; 17: 98-105. (Pubitemid 38529183)
124. Yahalom G, Schwartz R, Schwammenthal Y et al. Chronic kidney disease and clinical outcome in patients with acute stroke. Stroke 2009; 40: 1296-1303.
125. Ninomiya T, Perkovic V, Gallagher M et al. Lower blood pressure and risk of recurrent stroke in patients with chronic kidney disease: PROGRESS trial. Kidney Int 2008; 73: 963-970. (Pubitemid 351458323)
126. Mathew A, Eliasziw M, Devereaux PJ et al. Carotid endarterectomy benefits patients with CKD and symptomatic high-grade stenosis. J Am Soc Nephrol 2010; 21: 145-152.
127. Brott TG, Hobson RW, Howard G et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010; 363: 11-23.
128. Bonati LH, Dobson J, Algra A et al. Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individual patient data. Lancet 2010; 376: 1062-1073.
129. Stoner MC, Abbott WM, Wong DR et al. Defining the high-risk patient for carotid endarterectomy: an analysis of the prospective National Surgical Quality Improvement Program database. J Vasc Surg 2006; 43: 285-295.
130. Debing E, Van den Brande P. Chronic renal insufficiency and risk of early mortality in patients undergoing carotid endarterectomy. Ann Vasc Surg 2006; 20: 609-613. (Pubitemid 44953075)
131. Agrawal V, Rai B, Fellows J et al. In-hospital outcomes with thrombolytic therapy in patients with renal dysfunction presenting with acute ischaemic stroke. Nephrol Dial Transplant 2010; 25: 1150-1157.
132. Marti-Fabregas J, Bravo Y, Cocho D et al. Frequency and predictors of symptomatic intracerebral hemorrhage in patients with ischemic stroke treated with recombinant tissue plasminogen activator outside clinical trials. Cerebrovasc Dis 2007; 23: 85-90. (Pubitemid 46239146)
133. Kannel WB, Abbott RD, Savage DD et al. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982; 306: 1018-1022. (Pubitemid 12155370)
134. Wizemann V, Tong L, Satayathum S et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010; 77: 1098-1106.
135. Go AS, Fang MC, Udaltsova N et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009; 119: 1363-1369.
136. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867. (Pubitemid 351650486)
137. Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e257-e354. (Pubitemid 44252297)
138. Wilmer WA, Magro CM. Calciphylaxis: emerging concepts in prevention,
139. Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870. (Pubitemid 32537350)
140. Chan KE, Lazarus JM, Thadhani R et al. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009; 20: 2223-2233.
141. Chou CY, Kuo HL, Wang SM et al. Outcome of atrial fibrillation among patients with end-stage renal disease. Nephrol Dial Transplant 2010; 25: 1225-1230.
142. Yang F, Chou D, Schweitzer P et al. Warfarin in haemodialysis patients with atrial fibrillation: what benefit? Europace 2010; 12: 1666-1672.
143. Pisters R, Lane DA, Nieuwlaat R et al. A novel user-friendly score (HASBLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100.
144. Gage BF, Yan Y, Milligan PE et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151: 713-719. (Pubitemid 43290267)
145. Elliott MJ, Zimmerman D, Holden RM. Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates. Am J Kidney Dis 2007; 50: 433-440. (Pubitemid 47285456)
146. Chan KE, Lazarus JM, Thadhani R et al. Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol 2009; 20: 872-881.
147. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375. (Pubitemid 32424106)
148. Eikelboom JW, Weitz JI. New anticoagulants. Circulation 2010; 121: 1523-1532.
149. Maisel WH. Left atrial appendage occlusion-closure or just the beginning? N Engl J Med 2009; 360: 2601-2603.
150. Boehringer Ingelheim Pharmaceuticals I. Paradaxa (package insert). Ridgefield, CT, USA, 2010.
151. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
152. Boehringer Ingelheim Pharmaceuticals I. Advisory Committee Briefing Document: Dabigatran Etexilate (DE). 2010. Available at: http://www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeeting Materials/Drugs/ CardiovascularandRenalDrugsAdvisoryCommittee/UCM226009.pdf. Accessed 25 February 2011.
153. Stangier J, Rathgen K, Stahle H et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49: 259-268.
154. Marinigh R, Lane DA, Lip GY. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol 2011; 57: 1339-1348.
155. O'Hare AM, Glidden DV, Fox CS et al. High prevalence of peripheral arterial disease in persons with renal insufficiency: results from the National Health and Nutrition Examination Survey 1999-2000. Circulation 2004; 109: 320-323. (Pubitemid 38133897)
156. Lash JP, Go AS, Appel LJ et al. Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol 2009; 4: 1302-1311.
157. O'Hare A, Johansen K. Lower-extremity peripheral arterial disease among patients with end-stage renal disease. J Am Soc Nephrol 2001; 12: 2838-2847. (Pubitemid 33115433)
158. Miskulin D, Bragg-Gresham J, Gillespie BW et al. Key comorbid conditions that are predictive of survival among hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 1818-1826.
159. O'Hare AM, Vittinghoff E, Hsia J et al. Renal insufficiency and the risk of lower extremity peripheral arterial disease: results from the Heart and Estrogen/Progestin Replacement Study (HERS). J Am Soc Nephrol 2004; 15: 1046-1051. (Pubitemid 38375324)
160. O'Hare AM, Hsu CY, Bacchetti P et al. Peripheral vascular disease risk factors among patients undergoing hemodialysis. J Am Soc Nephrol 2002; 13: 497-503. (Pubitemid 34106293)
161. Boaz M, Weinstein T, Matas Z et al. Peripheral vascular disease and serum phosphorus in hemodialysis: a nested case-control study. Clin Nephrol 2005; 63: 98-105. (Pubitemid 40298044)
162. Cooper BA, Penne EL, Bartlett LH et al. Protein malnutrition and hypoalbuminemia as predictors of vascular events and mortality in ESRD. Am J Kidney Dis 2004; 43: 61-66. (Pubitemid 38049436)
163. Manns BJ, Burgess ED, Hyndman ME et al. Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease. Am J Kidney Dis 1999; 34: 669-677. (Pubitemid 29473054)
164. Makisalo H, Lepantalo M, Halme L et al. Peripheral arterial disease as a predictor of outcome after renal transplantation. Transpl Int 1998; 11(Suppl 1): S140-S143. (Pubitemid 128683527)
165. Ishii H, Kumada Y, Toriyama T et al. Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease. Clin J Am Soc Nephrol 2008; 3: 1034-1040.
166. Abbas AE, Goodman LM, Timmis R et al. Predictors of poor outcome in female patients undergoing endovascular intervention. J Interv Cardiol 2010; 23: 401-410.
167. Jaar BG, Astor BC, Berns JS et al. Predictors of amputation and survival following lower extremity revascularization in hemodialysis patients. Kidney Int 2004; 65: 613-620. (Pubitemid 38130656)
168. Zannetti S, L'Italien GJ, Cambria RP. Functional outcome after surgical treatment for intermittent claudication. J Vasc Surg 1996; 24: 65-73. (Pubitemid 26271956)
169. Reddan DN, Marcus RJ, Owen Jr WF et al. Long-term outcomes of revascularization for peripheral vascular disease in end-stage renal disease patients. Am J Kidney Dis 2001; 38: 57-63. (Pubitemid 32611759)
170. Eggers PW, Gohdes D, Pugh J. Nontraumatic lower extremity amputations in the Medicare end-stage renal disease population. Kidney Int 1999; 56: 1524-1533. (Pubitemid 29451259)
171. Speckman RA, Frankenfield DL, Roman SH et al. Diabetes is the strongest risk factor for lower-extremity amputation in new hemodialysis patients. Diabetes Care 2004; 27: 2198-2203. (Pubitemid 39167185)
172. O'Hare AM, Feinglass J, Sidawy AN et al. Impact of renal insufficiency on short-term morbidity and mortality after lower extremity revascularization: data from the Department of Veterans Affairs' National Surgical Quality Improvement Program. J Am Soc Nephrol 2003; 14: 1287-1295. (Pubitemid 36514668)
173. Ramdev P, Rayan SS, Sheahan M et al. A decade experience with infrainguinal revascularization in a dialysis-dependent patient population. J Vasc Surg 2002; 36: 969-974. (Pubitemid 35316071)
174. Rith-Najarian S, Gohdes D. Preventing amputations among patients with diabetes on dialysis. Diabetes Care 2000; 23: 1445-1446.
175. Myerburg RJ. Cardiac arrest and sudden cardiac death. In: Douglas P. Zipes, Peter Libby, Robert O. Bonow, Eugene Braunwald (eds). Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. Elsevier Saunders: Philadelphia, PA, 2005.
176. Pratt CM, Greenway PS, Schoenfeld MH et al. Exploration of the precision of classifying sudden cardiac death. Implications for the interpretation of clinical trials. Circulation 1996; 93: 519-524. (Pubitemid 26043611)
177. US Renal Data System. USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2005: 140-143.
178. Herzog CA. Can we prevent sudden cardiac death in dialysis patients? Clin J Am Soc Nephrol 2007; 2: 410-412.
179. US Renal Data System. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease & End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2010.
180. Pun PH, Lehrich RW, Smith SR et al. Predictors of survival after cardiac arrest in outpatient hemodialysis clinics. Clin J Am Soc Nephrol 2007; 2: 491-500.
181. Karnik JA, Young BS, Lew NL et al. Cardiac arrest and sudden death in dialysis units. Kidney Int 2001; 60: 350-357. (Pubitemid 32587574)
182. Lai M, Hung K, Huang J et al. Clinical findings and outcomes of intra-hemodialysis cardiopulmonary resuscitation. Am J Nephrol 1999; 19: 468-473. (Pubitemid 29397075)
183. Moss AH, Holley JL, Upton MB. Outcomes of cardiopulmonary resuscitation in dialysis patients. J Am Soc Nephrol 1992; 3: 1238-1243.
184. Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-2019. (Pubitemid 35461657)
185. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248. (Pubitemid 41058323)
186. Parekh RS, Plantinga LC, Kao WH et al. The association of sudden cardiac death with inflammation and other traditional risk factors. Kidney Int 2008; 74: 1335-1342.
187. Wang AY, Lam CW, Chan IH et al. Sudden cardiac death in end-stage renal disease patients: a 5-year prospective analysis. Hypertension 2010; 56: 210-216.
188. Goldenberg I, Moss AJ, McNitt S et al. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction. Am J Cardiol 2006; 98: 485-490. (Pubitemid 44162874)
189. Saxon LA, Bristow MR, Boehmer J et al. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. Circulation 2006; 114: 2766-2772. (Pubitemid 46018278)
190. Pun PH, Smarz TR, Honeycutt EF et al. Chronic kidney disease is associated with increased risk of sudden cardiac death among patients with coronary artery disease. Kidney Int 2009; 76: 652-658.
191. Deo R, Lin F, Vittinghoff E et al. Kidney dysfunction and sudden cardiac death among women with coronary heart disease. Hypertension 2008; 51: 1578-1582.
192. Deo R, Sotoodehnia N, Katz R et al. Cystatin C and sudden cardiac death risk in the elderly. Circ Cardiovasc Qual Outcomes 2010; 3: 159-164.
193. Rosenstock L, Olsen J. Firefighting and death from cardiovascular causes. N Engl J Med 2007; 356: 1261-1263. (Pubitemid 46465604)
194. Herzog CA, Mangrum JM, Passman R. Sudden cardiac death and dialysis patients. Semin Dialysis 2008; 21: 300-307.
195. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999; 10: 1606-1615. (Pubitemid 29297538)
196. Takeda K, Harada A, Okuda S et al. Sudden death in chronic dialysis patients. Nephrol Dial Transplant 1997; 12: 952-955. (Pubitemid 27216316)
197. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001; 345: 1473-1482.
198. Bleyer AJ, Hartman J, Brannon PC et al. Characteristics of sudden death in hemodialysis patients. Kidney Int 2006; 69: 2268-2273. (Pubitemid 43882115)
199. Davis TR, Young BA, Eisenberg MS et al. Outcome of cardiac arrests attended by emergency medical services staff at community outpatient dialysis centers. Kidney Int 2008; 73: 933-939. (Pubitemid 351458311)
200. Lafrance JP, Nolin L, Senecal L et al. Predictors and outcome of cardiopulmonary resuscitation (CPR) calls in a large haemodialysis unit over a seven-year period. Nephrol Dial Transplant 2006; 21: 1006-1012.
201. Bleyer AJ, Russell GB, Satko SG. Sudden and cardiac death rates in hemodialysis patients. Kidney Int 1999; 55: 1553-1559. (Pubitemid 29157156)
202. Pun PH, Lehrich RW, Honeycutt EF et al. Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics. Kidney Int 2011; 79: 218-227.
203. Kimmel PL, Miller G, Mendelson WB. Sleep apnea syndrome in chronic renal disease. Am J Med 1989; 86: 308-314. (Pubitemid 19081473)
204. Zoccali C, Mallamaci F, Tripepi G. Nocturnal hypoxemia predicts incident cardiovascular complications in dialysis patients. J Am Soc Nephrol 2002; 13: 729-733. (Pubitemid 34183939)
205. Paoletti E, Specchia C, Di MG et al. The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year survey. Nephrol Dial Transplant 2004; 19: 1829-1834. (Pubitemid 38961395)
206. Drechsler C, Krane V, Winkler K et al. Changes in adiponectin and the risk of sudden death, stroke, myocardial infarction, and mortality in hemodialysis patients. Kidney Int 2009; 76: 567-575.
207. Chan KE, Lazarus JM, Hakim RM. Digoxin associates with mortality in ESRD. J Am Soc Nephrol 2010; 21: 1550-1559.
208. Herzog CA, Li S, Weinhandl ED et al. Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators. Kidney Int 2005; 68: 818-825. (Pubitemid 43323139)
209. Charytan DM, Patrick AR, Liu J et al. Trends in the use and outcomes of implantable cardioverter defibrillators in patients undergoing dialysis in the United States. Am J Kidney Dis 2011. doi:10.1053/j.ajkd.2011.03.026 (e-pub ahead of print).
210. Dasgupta A, Montalvo J, Medendorp S et al. Increased complication rates of cardiac rhythm management devices in ESRD patients. Am J Kidney Dis 2007; 49: 656-663. (Pubitemid 46654496)
211. Aggarwal A, Wang Y, Rumsfeld JS et al. Clinical characteristics and in-hospital outcome of patients with end-stage renal disease on dialysis referred for implantable cardioverter-defibrillator implantation. Heart Rhythm 2009; 6: 1565-1571.
212. Abraham WT, Adamson PB, Bourge RC et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 2011; 377: 658-666.